Chelsea Ray, MD
Family Medicine · Munising, MINPI 1023370624
Payments from drug & device makers
Across 193 payments — averaging $19.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$456
- Amgen$413
- Boehringer Ingelheim$331
- AbbVie$273
- Novo Nordisk$271
- Pfizer$227
- plus $2K from 25 others
What the payments were for
- Food & beverage$3,79999%
- Education$501%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 23 | $456 |
| Amgen | 21 | $413 |
| Boehringer Ingelheim | 19 | $331 |
| AbbVie(2 entities) | 14 | $273 |
| Novo Nordisk | 15 | $271 |
| Pfizer | 11 | $227 |
| AstraZeneca | 7 | $198 |
| Axsome Therapeutics, Inc. | 10 | $197 |
| GSK | 11 | $195 |
| Lundbeck LLC | 8 | $167 |
| Otsuka America Pharmaceutical, Inc. | 7 | $162 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 9 | $162 |
| Supernus Pharmaceuticals, Inc. | 5 | $111 |
| Novartis | 5 | $93 |
| Merck | 5 | $91 |
| Sunovion Pharmaceuticals Inc. | 1 | $62 |
| Exact Sciences | 3 | $57 |
| Xeris Pharmaceuticals, Inc. | 3 | $56 |
| Johnson & Johnson | 1 | $54 |
| Regeneron Healthcare Solutions, Inc. | 2 | $36 |
| Teva Pharmaceuticals USA, Inc. | 3 | $35 |
| Corcept Therapeutics | 1 | $27 |
| Corium, LLC | 1 | $26 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
| Sanofi | 1 | $21 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $20 |
| Vanda Pharmaceuticals Inc. | 1 | $19 |
| Nestle Healthcare Nutrition Inc. | 1 | $18 |
| Bayer | 1 | $17 |
| Alkermes, Inc. | 1 | $17 |
| Astellas Pharma US Inc | 1 | $14 |
How this compares
$3,849 in reported general payments places this provider in the 85th percentile of 3,945 family medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 141 | $178,279 |
| EliquisApixaban | 117 | $109,444 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 113 | $90,134 |
| JardianceEmpagliflozin | 55 | $67,305 |
| Dupixent SyringeDupilumab | 17 | $65,741 |
| MounjaroTirzepatide | 51 | $60,451 |
| XareltoRivaroxaban | 61 | $55,805 |
| Xigduo XrDapaglifloz Propaned/Metformin | 60 | $53,763 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 36 | $42,490 |
| TrulicityDulaglutide | 34 | $41,368 |
| CreonLipase/Protease/Amylase | 13 | $40,066 |
| FarxigaDapagliflozin Propanediol | 30 | $29,252 |
| Tresiba Flextouch U-200Insulin Degludec | 23 | $24,464 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 17 | $24,177 |
| Humulin R U-500Insulin Regular, Human | 15 | $22,906 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $271 | $182,263169 claims |
| GSKTrelegy Ellipta, Arexvy, Breo Ellipta, Shingrix, Arnuity Ellipta | $195 | $125,435220 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $331 | $109,79691 claims |
| PfizerEliquis | $227 | $109,444117 claims |
| Lilly USA, LLCMounjaro, Trulicity | $456 | $101,81885 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $198 | $56,80372 claims |
| Johnson & JohnsonXarelto | $54 | $55,80561 claims |
| AbbVieCreon, Synthroid | $273 | $43,19550 claims |
| NovartisEntresto | $93 | $15,46619 claims |
| Astellas Pharma US IncMyrbetriq | $14 | $7,81816 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,945 family medicine providers in Michigan.
Other family medicine in Munising
- Derrick WilliamsonSouthfield$9.9M
- Rebecca RivardRoseville$7M
- Paul BensonBerkley$4.2M
- Michael HafranEast Lansing$2.7M
- Mitzie HewittBuckley$1.3M
- Loren ChudlerSouthfield$1.3M
- Solomon AmsterWhite Lake$981K
- Matt RosenbergJackson$559K
- Rhonda MejeurGrand Rapids$493K
- Steve LasaterSaint Johns$291K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.